T0	Participants 33 81	relapsing-remitting multiple sclerosis (SELECT):
T1	Participants 423 478	in patients with relapsing-remitting multiple sclerosis
T2	Participants 548 693	at 76 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, Turkey, and the UK between Feb 15, 2008, and May 14, 2010.
T3	Participants 694 763	Patients aged 18-55 years with relapsing-remitting multiple sclerosis
T4	Participants 1284 1391	FINDINGS 204 patients were assigned to receive placebo, 208 to daclizumab HYP 150 mg, and 209 to daclizumab
T5	Participants 2505 2545	treatment option for relapsing-remitting